Gyre Therapeutics
GYRE
51 hedge funds and large institutions have $13.7M invested in Gyre Therapeutics in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 26 closing their positions.
1.43% less ownership
Funds ownership: 7.81% → 6.39% (-1.4%)
22% less funds holding
Funds holding: 65 → 51 (-14)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
82% less capital invested
Capital invested by funds: $75.5M → $13.7M (-$61.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.95M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.35M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.17M |
| 4 |
Morgan Stanley
New York
|
+$994K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$751K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$10.8M |
| 2 |
2L
22NW LP
Seattle,
Washington
|
-$5.87M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$4.11M |
| 4 |
SCM
Sio Capital Management
New York
|
-$2.56M |
| 5 |
O
OrbiMed
New York
|
-$2.24M |
GYRE Hedge Fund Activity: Q4 2021 in Review
51 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2021, worth a combined $13.7M — down 82% from $75.5M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of GYRE and 12 opened new positions — a net loss of 14 holders — while 15 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.95M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $10.8M sold.
- 51 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2021, down from 65 in Q3 2021.
- Funds reported $13.7M of Gyre Therapeutics stock for Q4 2021, down 82% quarter-over-quarter.
- 12 funds opened new Gyre Therapeutics positions in Q4 2021 and 26 closed out, a net change of -14 holders.
- The largest Gyre Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $3.95M added.
- The largest Gyre Therapeutics seller in Q4 2021 was Stonepine Capital Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q4 2021.